Axsome Therapeutics (AXSM) Current Leases (2020 - 2026)
Axsome Therapeutics recorded quarterly Current Leases of $628000.0 in Q1 2026, down 75.32% quarter-over-quarter from $2.5 million in Q4 2025, and down 65.42% year-over-year from $1.8 million in Q1 2025.
Axsome Therapeutics' Current Leases history runs 7 years deep, the most recent figure standing at $628000.0 for Q1 2026.
- In Q1 2026, Current Leases fell 65.42% year-over-year to $628000.0; the TTM figure through Mar 2026 stood at $628000.0 (down 65.42% YoY), while the FY2025 annual figure was $2.5 million, up 38.69% from the prior year.
- Current Leases came in at $628000.0 for Q1 2026 at Axsome Therapeutics, down from $2.5 million in the prior quarter.
- In the past five years, Current Leases ranged from a high of $2.5 million in Q4 2025 to a low of $108000.0 in Q1 2023.
- A 5-year average of $1.0 million and a median of $709120.0 in 2022 frame the typical range for Current Leases.
- Across the five-year window, Current Leases sank 88.83% in 2023 and soared 485.19% in 2024, its largest moves.
- Axsome Therapeutics' Current Leases stood at $425000.0 in 2022, then surged by 198.12% to $1.3 million in 2023, then jumped by 44.83% to $1.8 million in 2024, then jumped by 38.69% to $2.5 million in 2025, then plunged by 75.32% to $628000.0 in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $628000.0, $2.5 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 83,991.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 720.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 45.66 Mn |
| 10 | Axsome Therapeutics | 11.82 Bn | 11.51 Bn | 176.48 Mn | 628,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 628,000.00 |
| Dec 31, 2025 | 2.55 Mn |
| Sep 30, 2025 | 2.50 Mn |
| Jun 30, 2025 | 337,000.00 |
| Mar 31, 2025 | 1.82 Mn |
| Dec 31, 2024 | 1.84 Mn |
| Sep 30, 2024 | 1.28 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | 632,000.00 |
| Dec 31, 2023 | 1.27 Mn |
| Sep 30, 2023 | 438,000.00 |
| Jun 30, 2023 | 350,000.00 |
| Mar 31, 2023 | 108,000.00 |
| Dec 31, 2022 | 425,000.00 |
| Sep 30, 2022 | 416,876.00 |
| Jun 30, 2022 | 709,120.00 |
| Mar 31, 2022 | 967,248.00 |
| Dec 31, 2021 | 620,675.00 |
| Sep 30, 2021 | 880,116.00 |
| Jun 30, 2021 | 1.09 Mn |
| Mar 31, 2021 | 1.20 Mn |
| Dec 31, 2020 | 1.22 Mn |